American Research & Management Company’s Protara Therapeutics TARA Stock Holding History

American Research & Management Company’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-25	Closed	-$8K	–	363
2016 Q1	$8K	Hold	25	–	–	﹤0.01%	278
2015 Q4	$16K	Hold	25	–	–	0.01%	241
2015 Q3	$14K	Hold	25	–	–	0.01%	255
2015 Q2	$18K	Hold	25	–	–	0.01%	246
2015 Q1	$12K	Hold	25	–	–	﹤0.01%	267
2014 Q4	$10K	Buy	+25	New	+$10.1K	﹤0.01%	276

Other funds holding TARA

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

American Research & Management Company's TARA Position: Q2 2016 in Review

American Research & Management Company sold out of Protara Therapeutics (TARA) in Q2 2016, closing a stake of 25 shares — an estimated $8K sold.

American Research & Management Company first reported a position in TARA in Q4 2014 and held it in 6 quarters. The position peaked at $18K in Q2 2015. 32 funds tracked by Wall St. Rank hold TARA as of Q2 2016.

American Research & Management Company reported no remaining Protara Therapeutics position as of Q2 2016 after selling out during the quarter.
American Research & Management Company sold 25 Protara Therapeutics shares in Q2 2016, an estimated $8K.
American Research & Management Company first reported a position in Protara Therapeutics in Q4 2014 and held it in 6 quarters.
American Research & Management Company's Protara Therapeutics position peaked at $18K in Q2 2015.
32 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2016.

Based on American Research & Management Company's 13F filing for Q2 2016, filed 29 Jul 2016.